Global Topical Hydrocortisone Market

Topical Hydrocortisone Comprehensive Study by Application (Insect bites, Poison oak/ivy, Eczema, Dermatitis, Others), Form (Ointment, Cream, Solution (liquid), Spray, Lotion), Drug Type (OTC, Prescribed), End User (Hospitals, Dermatology clinics, Pharmacies, Others) Players and Region - Global Market Outlook to 2026

Topical Hydrocortisone Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Topical Hydrocortisone Market Scope
Hydrocortisone is in a class of medicines named corticosteroids, Hydrocortisone topical is applied to treat redness, swelling, itching, and various skin conditions. It works by stimulating natural substances in the skin to reduce swelling, redness, and itching. This medicine is used to administrate a kind of skin diseases such as insect bites, poison oak/ivy, eczema, dermatitis, and the outer female genitals, anal itching. According to the research done in the United States 2 million people are infected with bacteria that are resistant to antibiotics, and around 23,000 people die due to such infections is one of the leading factors of growth of the topical hydrocortisone market to treat different skin disorders.

The Topical Hydrocortisone market study is segmented, by Application (Insect bites, Poison oak/ivy, Eczema, Dermatitis and Others) and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Topical Hydrocortisone market throughout the predicted period.

Pfizer Inc (United States), AstraZeneca plc. (United Kingdom), Sun Pharmaceutical Industries Ltd. (India), Taro Pharmaceutical Industries Ltd. (United States), Merck & Co., Inc.(United States), Actimis Pharmaceuticals (Germany), Siemens Healthcare (Germany), Sanofi (France), Novartis International AG (Switzerland) and Eli Lilly and Co. (United States) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Topical Hydrocortisone market by Type, Application and Region.

On the basis of geography, the market of Topical Hydrocortisone has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).




Market Trend
  • Continuous research in the treatment of various skin conditions

Market Drivers
  • Rising worldwide skin infection cases across the globe
  • Rising number of the dermatology clinics

Opportunities
  • The rise in new product launches
  • Increase in investment in the healthcare domain by governments in the region

Restraints
  • Adverse allergic effect of the topical hydrocortisone

Challenges
  • Overdose can cause serious symptoms such as passing out or trouble breathing


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Topical Hydrocortisone Manufacturer, Government Regulatory and Research Organizations and End-Use Industry

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase

Report Objectives / Segmentation Covered

By Application
  • Insect bites
  • Poison oak/ivy
  • Eczema
  • Dermatitis
  • Others
By Form
  • Ointment
  • Cream
  • Solution (liquid)
  • Spray
  • Lotion

By Drug Type
  • OTC
  • Prescribed

By End User
  • Hospitals
  • Dermatology clinics
  • Pharmacies
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising worldwide skin infection cases across the globe
      • 3.2.2. Rising number of the dermatology clinics
    • 3.3. Market Challenges
      • 3.3.1. Overdose can cause serious symptoms such as passing out or trouble breathing
    • 3.4. Market Trends
      • 3.4.1. Continuous research in the treatment of various skin conditions
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Topical Hydrocortisone, by Application, Form, Drug Type , End User and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Topical Hydrocortisone (Value)
      • 5.2.1. Global Topical Hydrocortisone by: Application (Value)
        • 5.2.1.1. Insect bites
        • 5.2.1.2. Poison oak/ivy
        • 5.2.1.3. Eczema
        • 5.2.1.4. Dermatitis
        • 5.2.1.5. Others
      • 5.2.2. Global Topical Hydrocortisone by: Form (Value)
        • 5.2.2.1. Ointment
        • 5.2.2.2. Cream
        • 5.2.2.3. Solution (liquid)
        • 5.2.2.4. Spray
        • 5.2.2.5. Lotion
      • 5.2.3. Global Topical Hydrocortisone by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Dermatology clinics
        • 5.2.3.3. Pharmacies
        • 5.2.3.4. Others
      • 5.2.4. Global Topical Hydrocortisone Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Topical Hydrocortisone: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer Inc (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. AstraZeneca plc. (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sun Pharmaceutical Industries Ltd. (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Taro Pharmaceutical Industries Ltd. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck & Co., Inc.(United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Actimis Pharmaceuticals (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Siemens Healthcare (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sanofi (France)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novartis International AG (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Eli Lilly and Co. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Topical Hydrocortisone Sale, by Application, Form, Drug Type , End User and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Topical Hydrocortisone (Value)
      • 7.2.1. Global Topical Hydrocortisone by: Application (Value)
        • 7.2.1.1. Insect bites
        • 7.2.1.2. Poison oak/ivy
        • 7.2.1.3. Eczema
        • 7.2.1.4. Dermatitis
        • 7.2.1.5. Others
      • 7.2.2. Global Topical Hydrocortisone by: Form (Value)
        • 7.2.2.1. Ointment
        • 7.2.2.2. Cream
        • 7.2.2.3. Solution (liquid)
        • 7.2.2.4. Spray
        • 7.2.2.5. Lotion
      • 7.2.3. Global Topical Hydrocortisone by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Dermatology clinics
        • 7.2.3.3. Pharmacies
        • 7.2.3.4. Others
      • 7.2.4. Global Topical Hydrocortisone Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Topical Hydrocortisone: by Application(USD Million)
  • Table 2. Topical Hydrocortisone Insect bites , by Region USD Million (2015-2020)
  • Table 3. Topical Hydrocortisone Poison oak/ivy , by Region USD Million (2015-2020)
  • Table 4. Topical Hydrocortisone Eczema , by Region USD Million (2015-2020)
  • Table 5. Topical Hydrocortisone Dermatitis , by Region USD Million (2015-2020)
  • Table 6. Topical Hydrocortisone Others , by Region USD Million (2015-2020)
  • Table 7. Topical Hydrocortisone: by Form(USD Million)
  • Table 8. Topical Hydrocortisone Ointment , by Region USD Million (2015-2020)
  • Table 9. Topical Hydrocortisone Cream , by Region USD Million (2015-2020)
  • Table 10. Topical Hydrocortisone Solution (liquid) , by Region USD Million (2015-2020)
  • Table 11. Topical Hydrocortisone Spray , by Region USD Million (2015-2020)
  • Table 12. Topical Hydrocortisone Lotion , by Region USD Million (2015-2020)
  • Table 13. Topical Hydrocortisone: by End User(USD Million)
  • Table 14. Topical Hydrocortisone Hospitals , by Region USD Million (2015-2020)
  • Table 15. Topical Hydrocortisone Dermatology clinics , by Region USD Million (2015-2020)
  • Table 16. Topical Hydrocortisone Pharmacies , by Region USD Million (2015-2020)
  • Table 17. Topical Hydrocortisone Others , by Region USD Million (2015-2020)
  • Table 18. South America Topical Hydrocortisone, by Country USD Million (2015-2020)
  • Table 19. South America Topical Hydrocortisone, by Application USD Million (2015-2020)
  • Table 20. South America Topical Hydrocortisone, by Form USD Million (2015-2020)
  • Table 21. South America Topical Hydrocortisone, by Drug Type USD Million (2015-2020)
  • Table 22. South America Topical Hydrocortisone, by End User USD Million (2015-2020)
  • Table 23. Brazil Topical Hydrocortisone, by Application USD Million (2015-2020)
  • Table 24. Brazil Topical Hydrocortisone, by Form USD Million (2015-2020)
  • Table 25. Brazil Topical Hydrocortisone, by Drug Type USD Million (2015-2020)
  • Table 26. Brazil Topical Hydrocortisone, by End User USD Million (2015-2020)
  • Table 27. Argentina Topical Hydrocortisone, by Application USD Million (2015-2020)
  • Table 28. Argentina Topical Hydrocortisone, by Form USD Million (2015-2020)
  • Table 29. Argentina Topical Hydrocortisone, by Drug Type USD Million (2015-2020)
  • Table 30. Argentina Topical Hydrocortisone, by End User USD Million (2015-2020)
  • Table 31. Rest of South America Topical Hydrocortisone, by Application USD Million (2015-2020)
  • Table 32. Rest of South America Topical Hydrocortisone, by Form USD Million (2015-2020)
  • Table 33. Rest of South America Topical Hydrocortisone, by Drug Type USD Million (2015-2020)
  • Table 34. Rest of South America Topical Hydrocortisone, by End User USD Million (2015-2020)
  • Table 35. Asia Pacific Topical Hydrocortisone, by Country USD Million (2015-2020)
  • Table 36. Asia Pacific Topical Hydrocortisone, by Application USD Million (2015-2020)
  • Table 37. Asia Pacific Topical Hydrocortisone, by Form USD Million (2015-2020)
  • Table 38. Asia Pacific Topical Hydrocortisone, by Drug Type USD Million (2015-2020)
  • Table 39. Asia Pacific Topical Hydrocortisone, by End User USD Million (2015-2020)
  • Table 40. China Topical Hydrocortisone, by Application USD Million (2015-2020)
  • Table 41. China Topical Hydrocortisone, by Form USD Million (2015-2020)
  • Table 42. China Topical Hydrocortisone, by Drug Type USD Million (2015-2020)
  • Table 43. China Topical Hydrocortisone, by End User USD Million (2015-2020)
  • Table 44. Japan Topical Hydrocortisone, by Application USD Million (2015-2020)
  • Table 45. Japan Topical Hydrocortisone, by Form USD Million (2015-2020)
  • Table 46. Japan Topical Hydrocortisone, by Drug Type USD Million (2015-2020)
  • Table 47. Japan Topical Hydrocortisone, by End User USD Million (2015-2020)
  • Table 48. India Topical Hydrocortisone, by Application USD Million (2015-2020)
  • Table 49. India Topical Hydrocortisone, by Form USD Million (2015-2020)
  • Table 50. India Topical Hydrocortisone, by Drug Type USD Million (2015-2020)
  • Table 51. India Topical Hydrocortisone, by End User USD Million (2015-2020)
  • Table 52. South Korea Topical Hydrocortisone, by Application USD Million (2015-2020)
  • Table 53. South Korea Topical Hydrocortisone, by Form USD Million (2015-2020)
  • Table 54. South Korea Topical Hydrocortisone, by Drug Type USD Million (2015-2020)
  • Table 55. South Korea Topical Hydrocortisone, by End User USD Million (2015-2020)
  • Table 56. Taiwan Topical Hydrocortisone, by Application USD Million (2015-2020)
  • Table 57. Taiwan Topical Hydrocortisone, by Form USD Million (2015-2020)
  • Table 58. Taiwan Topical Hydrocortisone, by Drug Type USD Million (2015-2020)
  • Table 59. Taiwan Topical Hydrocortisone, by End User USD Million (2015-2020)
  • Table 60. Australia Topical Hydrocortisone, by Application USD Million (2015-2020)
  • Table 61. Australia Topical Hydrocortisone, by Form USD Million (2015-2020)
  • Table 62. Australia Topical Hydrocortisone, by Drug Type USD Million (2015-2020)
  • Table 63. Australia Topical Hydrocortisone, by End User USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Topical Hydrocortisone, by Application USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Topical Hydrocortisone, by Form USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Topical Hydrocortisone, by Drug Type USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Topical Hydrocortisone, by End User USD Million (2015-2020)
  • Table 68. Europe Topical Hydrocortisone, by Country USD Million (2015-2020)
  • Table 69. Europe Topical Hydrocortisone, by Application USD Million (2015-2020)
  • Table 70. Europe Topical Hydrocortisone, by Form USD Million (2015-2020)
  • Table 71. Europe Topical Hydrocortisone, by Drug Type USD Million (2015-2020)
  • Table 72. Europe Topical Hydrocortisone, by End User USD Million (2015-2020)
  • Table 73. Germany Topical Hydrocortisone, by Application USD Million (2015-2020)
  • Table 74. Germany Topical Hydrocortisone, by Form USD Million (2015-2020)
  • Table 75. Germany Topical Hydrocortisone, by Drug Type USD Million (2015-2020)
  • Table 76. Germany Topical Hydrocortisone, by End User USD Million (2015-2020)
  • Table 77. France Topical Hydrocortisone, by Application USD Million (2015-2020)
  • Table 78. France Topical Hydrocortisone, by Form USD Million (2015-2020)
  • Table 79. France Topical Hydrocortisone, by Drug Type USD Million (2015-2020)
  • Table 80. France Topical Hydrocortisone, by End User USD Million (2015-2020)
  • Table 81. Italy Topical Hydrocortisone, by Application USD Million (2015-2020)
  • Table 82. Italy Topical Hydrocortisone, by Form USD Million (2015-2020)
  • Table 83. Italy Topical Hydrocortisone, by Drug Type USD Million (2015-2020)
  • Table 84. Italy Topical Hydrocortisone, by End User USD Million (2015-2020)
  • Table 85. United Kingdom Topical Hydrocortisone, by Application USD Million (2015-2020)
  • Table 86. United Kingdom Topical Hydrocortisone, by Form USD Million (2015-2020)
  • Table 87. United Kingdom Topical Hydrocortisone, by Drug Type USD Million (2015-2020)
  • Table 88. United Kingdom Topical Hydrocortisone, by End User USD Million (2015-2020)
  • Table 89. Netherlands Topical Hydrocortisone, by Application USD Million (2015-2020)
  • Table 90. Netherlands Topical Hydrocortisone, by Form USD Million (2015-2020)
  • Table 91. Netherlands Topical Hydrocortisone, by Drug Type USD Million (2015-2020)
  • Table 92. Netherlands Topical Hydrocortisone, by End User USD Million (2015-2020)
  • Table 93. Rest of Europe Topical Hydrocortisone, by Application USD Million (2015-2020)
  • Table 94. Rest of Europe Topical Hydrocortisone, by Form USD Million (2015-2020)
  • Table 95. Rest of Europe Topical Hydrocortisone, by Drug Type USD Million (2015-2020)
  • Table 96. Rest of Europe Topical Hydrocortisone, by End User USD Million (2015-2020)
  • Table 97. MEA Topical Hydrocortisone, by Country USD Million (2015-2020)
  • Table 98. MEA Topical Hydrocortisone, by Application USD Million (2015-2020)
  • Table 99. MEA Topical Hydrocortisone, by Form USD Million (2015-2020)
  • Table 100. MEA Topical Hydrocortisone, by Drug Type USD Million (2015-2020)
  • Table 101. MEA Topical Hydrocortisone, by End User USD Million (2015-2020)
  • Table 102. Middle East Topical Hydrocortisone, by Application USD Million (2015-2020)
  • Table 103. Middle East Topical Hydrocortisone, by Form USD Million (2015-2020)
  • Table 104. Middle East Topical Hydrocortisone, by Drug Type USD Million (2015-2020)
  • Table 105. Middle East Topical Hydrocortisone, by End User USD Million (2015-2020)
  • Table 106. Africa Topical Hydrocortisone, by Application USD Million (2015-2020)
  • Table 107. Africa Topical Hydrocortisone, by Form USD Million (2015-2020)
  • Table 108. Africa Topical Hydrocortisone, by Drug Type USD Million (2015-2020)
  • Table 109. Africa Topical Hydrocortisone, by End User USD Million (2015-2020)
  • Table 110. North America Topical Hydrocortisone, by Country USD Million (2015-2020)
  • Table 111. North America Topical Hydrocortisone, by Application USD Million (2015-2020)
  • Table 112. North America Topical Hydrocortisone, by Form USD Million (2015-2020)
  • Table 113. North America Topical Hydrocortisone, by Drug Type USD Million (2015-2020)
  • Table 114. North America Topical Hydrocortisone, by End User USD Million (2015-2020)
  • Table 115. United States Topical Hydrocortisone, by Application USD Million (2015-2020)
  • Table 116. United States Topical Hydrocortisone, by Form USD Million (2015-2020)
  • Table 117. United States Topical Hydrocortisone, by Drug Type USD Million (2015-2020)
  • Table 118. United States Topical Hydrocortisone, by End User USD Million (2015-2020)
  • Table 119. Canada Topical Hydrocortisone, by Application USD Million (2015-2020)
  • Table 120. Canada Topical Hydrocortisone, by Form USD Million (2015-2020)
  • Table 121. Canada Topical Hydrocortisone, by Drug Type USD Million (2015-2020)
  • Table 122. Canada Topical Hydrocortisone, by End User USD Million (2015-2020)
  • Table 123. Mexico Topical Hydrocortisone, by Application USD Million (2015-2020)
  • Table 124. Mexico Topical Hydrocortisone, by Form USD Million (2015-2020)
  • Table 125. Mexico Topical Hydrocortisone, by Drug Type USD Million (2015-2020)
  • Table 126. Mexico Topical Hydrocortisone, by End User USD Million (2015-2020)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Topical Hydrocortisone: by Application(USD Million)
  • Table 138. Topical Hydrocortisone Insect bites , by Region USD Million (2021-2026)
  • Table 139. Topical Hydrocortisone Poison oak/ivy , by Region USD Million (2021-2026)
  • Table 140. Topical Hydrocortisone Eczema , by Region USD Million (2021-2026)
  • Table 141. Topical Hydrocortisone Dermatitis , by Region USD Million (2021-2026)
  • Table 142. Topical Hydrocortisone Others , by Region USD Million (2021-2026)
  • Table 143. Topical Hydrocortisone: by Form(USD Million)
  • Table 144. Topical Hydrocortisone Ointment , by Region USD Million (2021-2026)
  • Table 145. Topical Hydrocortisone Cream , by Region USD Million (2021-2026)
  • Table 146. Topical Hydrocortisone Solution (liquid) , by Region USD Million (2021-2026)
  • Table 147. Topical Hydrocortisone Spray , by Region USD Million (2021-2026)
  • Table 148. Topical Hydrocortisone Lotion , by Region USD Million (2021-2026)
  • Table 149. Topical Hydrocortisone: by End User(USD Million)
  • Table 150. Topical Hydrocortisone Hospitals , by Region USD Million (2021-2026)
  • Table 151. Topical Hydrocortisone Dermatology clinics , by Region USD Million (2021-2026)
  • Table 152. Topical Hydrocortisone Pharmacies , by Region USD Million (2021-2026)
  • Table 153. Topical Hydrocortisone Others , by Region USD Million (2021-2026)
  • Table 154. South America Topical Hydrocortisone, by Country USD Million (2021-2026)
  • Table 155. South America Topical Hydrocortisone, by Application USD Million (2021-2026)
  • Table 156. South America Topical Hydrocortisone, by Form USD Million (2021-2026)
  • Table 157. South America Topical Hydrocortisone, by Drug Type USD Million (2021-2026)
  • Table 158. South America Topical Hydrocortisone, by End User USD Million (2021-2026)
  • Table 159. Brazil Topical Hydrocortisone, by Application USD Million (2021-2026)
  • Table 160. Brazil Topical Hydrocortisone, by Form USD Million (2021-2026)
  • Table 161. Brazil Topical Hydrocortisone, by Drug Type USD Million (2021-2026)
  • Table 162. Brazil Topical Hydrocortisone, by End User USD Million (2021-2026)
  • Table 163. Argentina Topical Hydrocortisone, by Application USD Million (2021-2026)
  • Table 164. Argentina Topical Hydrocortisone, by Form USD Million (2021-2026)
  • Table 165. Argentina Topical Hydrocortisone, by Drug Type USD Million (2021-2026)
  • Table 166. Argentina Topical Hydrocortisone, by End User USD Million (2021-2026)
  • Table 167. Rest of South America Topical Hydrocortisone, by Application USD Million (2021-2026)
  • Table 168. Rest of South America Topical Hydrocortisone, by Form USD Million (2021-2026)
  • Table 169. Rest of South America Topical Hydrocortisone, by Drug Type USD Million (2021-2026)
  • Table 170. Rest of South America Topical Hydrocortisone, by End User USD Million (2021-2026)
  • Table 171. Asia Pacific Topical Hydrocortisone, by Country USD Million (2021-2026)
  • Table 172. Asia Pacific Topical Hydrocortisone, by Application USD Million (2021-2026)
  • Table 173. Asia Pacific Topical Hydrocortisone, by Form USD Million (2021-2026)
  • Table 174. Asia Pacific Topical Hydrocortisone, by Drug Type USD Million (2021-2026)
  • Table 175. Asia Pacific Topical Hydrocortisone, by End User USD Million (2021-2026)
  • Table 176. China Topical Hydrocortisone, by Application USD Million (2021-2026)
  • Table 177. China Topical Hydrocortisone, by Form USD Million (2021-2026)
  • Table 178. China Topical Hydrocortisone, by Drug Type USD Million (2021-2026)
  • Table 179. China Topical Hydrocortisone, by End User USD Million (2021-2026)
  • Table 180. Japan Topical Hydrocortisone, by Application USD Million (2021-2026)
  • Table 181. Japan Topical Hydrocortisone, by Form USD Million (2021-2026)
  • Table 182. Japan Topical Hydrocortisone, by Drug Type USD Million (2021-2026)
  • Table 183. Japan Topical Hydrocortisone, by End User USD Million (2021-2026)
  • Table 184. India Topical Hydrocortisone, by Application USD Million (2021-2026)
  • Table 185. India Topical Hydrocortisone, by Form USD Million (2021-2026)
  • Table 186. India Topical Hydrocortisone, by Drug Type USD Million (2021-2026)
  • Table 187. India Topical Hydrocortisone, by End User USD Million (2021-2026)
  • Table 188. South Korea Topical Hydrocortisone, by Application USD Million (2021-2026)
  • Table 189. South Korea Topical Hydrocortisone, by Form USD Million (2021-2026)
  • Table 190. South Korea Topical Hydrocortisone, by Drug Type USD Million (2021-2026)
  • Table 191. South Korea Topical Hydrocortisone, by End User USD Million (2021-2026)
  • Table 192. Taiwan Topical Hydrocortisone, by Application USD Million (2021-2026)
  • Table 193. Taiwan Topical Hydrocortisone, by Form USD Million (2021-2026)
  • Table 194. Taiwan Topical Hydrocortisone, by Drug Type USD Million (2021-2026)
  • Table 195. Taiwan Topical Hydrocortisone, by End User USD Million (2021-2026)
  • Table 196. Australia Topical Hydrocortisone, by Application USD Million (2021-2026)
  • Table 197. Australia Topical Hydrocortisone, by Form USD Million (2021-2026)
  • Table 198. Australia Topical Hydrocortisone, by Drug Type USD Million (2021-2026)
  • Table 199. Australia Topical Hydrocortisone, by End User USD Million (2021-2026)
  • Table 200. Rest of Asia-Pacific Topical Hydrocortisone, by Application USD Million (2021-2026)
  • Table 201. Rest of Asia-Pacific Topical Hydrocortisone, by Form USD Million (2021-2026)
  • Table 202. Rest of Asia-Pacific Topical Hydrocortisone, by Drug Type USD Million (2021-2026)
  • Table 203. Rest of Asia-Pacific Topical Hydrocortisone, by End User USD Million (2021-2026)
  • Table 204. Europe Topical Hydrocortisone, by Country USD Million (2021-2026)
  • Table 205. Europe Topical Hydrocortisone, by Application USD Million (2021-2026)
  • Table 206. Europe Topical Hydrocortisone, by Form USD Million (2021-2026)
  • Table 207. Europe Topical Hydrocortisone, by Drug Type USD Million (2021-2026)
  • Table 208. Europe Topical Hydrocortisone, by End User USD Million (2021-2026)
  • Table 209. Germany Topical Hydrocortisone, by Application USD Million (2021-2026)
  • Table 210. Germany Topical Hydrocortisone, by Form USD Million (2021-2026)
  • Table 211. Germany Topical Hydrocortisone, by Drug Type USD Million (2021-2026)
  • Table 212. Germany Topical Hydrocortisone, by End User USD Million (2021-2026)
  • Table 213. France Topical Hydrocortisone, by Application USD Million (2021-2026)
  • Table 214. France Topical Hydrocortisone, by Form USD Million (2021-2026)
  • Table 215. France Topical Hydrocortisone, by Drug Type USD Million (2021-2026)
  • Table 216. France Topical Hydrocortisone, by End User USD Million (2021-2026)
  • Table 217. Italy Topical Hydrocortisone, by Application USD Million (2021-2026)
  • Table 218. Italy Topical Hydrocortisone, by Form USD Million (2021-2026)
  • Table 219. Italy Topical Hydrocortisone, by Drug Type USD Million (2021-2026)
  • Table 220. Italy Topical Hydrocortisone, by End User USD Million (2021-2026)
  • Table 221. United Kingdom Topical Hydrocortisone, by Application USD Million (2021-2026)
  • Table 222. United Kingdom Topical Hydrocortisone, by Form USD Million (2021-2026)
  • Table 223. United Kingdom Topical Hydrocortisone, by Drug Type USD Million (2021-2026)
  • Table 224. United Kingdom Topical Hydrocortisone, by End User USD Million (2021-2026)
  • Table 225. Netherlands Topical Hydrocortisone, by Application USD Million (2021-2026)
  • Table 226. Netherlands Topical Hydrocortisone, by Form USD Million (2021-2026)
  • Table 227. Netherlands Topical Hydrocortisone, by Drug Type USD Million (2021-2026)
  • Table 228. Netherlands Topical Hydrocortisone, by End User USD Million (2021-2026)
  • Table 229. Rest of Europe Topical Hydrocortisone, by Application USD Million (2021-2026)
  • Table 230. Rest of Europe Topical Hydrocortisone, by Form USD Million (2021-2026)
  • Table 231. Rest of Europe Topical Hydrocortisone, by Drug Type USD Million (2021-2026)
  • Table 232. Rest of Europe Topical Hydrocortisone, by End User USD Million (2021-2026)
  • Table 233. MEA Topical Hydrocortisone, by Country USD Million (2021-2026)
  • Table 234. MEA Topical Hydrocortisone, by Application USD Million (2021-2026)
  • Table 235. MEA Topical Hydrocortisone, by Form USD Million (2021-2026)
  • Table 236. MEA Topical Hydrocortisone, by Drug Type USD Million (2021-2026)
  • Table 237. MEA Topical Hydrocortisone, by End User USD Million (2021-2026)
  • Table 238. Middle East Topical Hydrocortisone, by Application USD Million (2021-2026)
  • Table 239. Middle East Topical Hydrocortisone, by Form USD Million (2021-2026)
  • Table 240. Middle East Topical Hydrocortisone, by Drug Type USD Million (2021-2026)
  • Table 241. Middle East Topical Hydrocortisone, by End User USD Million (2021-2026)
  • Table 242. Africa Topical Hydrocortisone, by Application USD Million (2021-2026)
  • Table 243. Africa Topical Hydrocortisone, by Form USD Million (2021-2026)
  • Table 244. Africa Topical Hydrocortisone, by Drug Type USD Million (2021-2026)
  • Table 245. Africa Topical Hydrocortisone, by End User USD Million (2021-2026)
  • Table 246. North America Topical Hydrocortisone, by Country USD Million (2021-2026)
  • Table 247. North America Topical Hydrocortisone, by Application USD Million (2021-2026)
  • Table 248. North America Topical Hydrocortisone, by Form USD Million (2021-2026)
  • Table 249. North America Topical Hydrocortisone, by Drug Type USD Million (2021-2026)
  • Table 250. North America Topical Hydrocortisone, by End User USD Million (2021-2026)
  • Table 251. United States Topical Hydrocortisone, by Application USD Million (2021-2026)
  • Table 252. United States Topical Hydrocortisone, by Form USD Million (2021-2026)
  • Table 253. United States Topical Hydrocortisone, by Drug Type USD Million (2021-2026)
  • Table 254. United States Topical Hydrocortisone, by End User USD Million (2021-2026)
  • Table 255. Canada Topical Hydrocortisone, by Application USD Million (2021-2026)
  • Table 256. Canada Topical Hydrocortisone, by Form USD Million (2021-2026)
  • Table 257. Canada Topical Hydrocortisone, by Drug Type USD Million (2021-2026)
  • Table 258. Canada Topical Hydrocortisone, by End User USD Million (2021-2026)
  • Table 259. Mexico Topical Hydrocortisone, by Application USD Million (2021-2026)
  • Table 260. Mexico Topical Hydrocortisone, by Form USD Million (2021-2026)
  • Table 261. Mexico Topical Hydrocortisone, by Drug Type USD Million (2021-2026)
  • Table 262. Mexico Topical Hydrocortisone, by End User USD Million (2021-2026)
  • Table 263. Research Programs/Design for This Report
  • Table 264. Key Data Information from Secondary Sources
  • Table 265. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Topical Hydrocortisone: by Application USD Million (2015-2020)
  • Figure 5. Global Topical Hydrocortisone: by Form USD Million (2015-2020)
  • Figure 6. Global Topical Hydrocortisone: by End User USD Million (2015-2020)
  • Figure 7. South America Topical Hydrocortisone Share (%), by Country
  • Figure 8. Asia Pacific Topical Hydrocortisone Share (%), by Country
  • Figure 9. Europe Topical Hydrocortisone Share (%), by Country
  • Figure 10. MEA Topical Hydrocortisone Share (%), by Country
  • Figure 11. North America Topical Hydrocortisone Share (%), by Country
  • Figure 12. Global Topical Hydrocortisone share by Players 2020 (%)
  • Figure 13. Global Topical Hydrocortisone share by Players (Top 3) 2020(%)
  • Figure 14. Global Topical Hydrocortisone share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Pfizer Inc (United States) Revenue, Net Income and Gross profit
  • Figure 17. Pfizer Inc (United States) Revenue: by Geography 2020
  • Figure 18. AstraZeneca plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 19. AstraZeneca plc. (United Kingdom) Revenue: by Geography 2020
  • Figure 20. Sun Pharmaceutical Industries Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 21. Sun Pharmaceutical Industries Ltd. (India) Revenue: by Geography 2020
  • Figure 22. Taro Pharmaceutical Industries Ltd. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Taro Pharmaceutical Industries Ltd. (United States) Revenue: by Geography 2020
  • Figure 24. Merck & Co., Inc.(United States) Revenue, Net Income and Gross profit
  • Figure 25. Merck & Co., Inc.(United States) Revenue: by Geography 2020
  • Figure 26. Actimis Pharmaceuticals (Germany) Revenue, Net Income and Gross profit
  • Figure 27. Actimis Pharmaceuticals (Germany) Revenue: by Geography 2020
  • Figure 28. Siemens Healthcare (Germany) Revenue, Net Income and Gross profit
  • Figure 29. Siemens Healthcare (Germany) Revenue: by Geography 2020
  • Figure 30. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 31. Sanofi (France) Revenue: by Geography 2020
  • Figure 32. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. Novartis International AG (Switzerland) Revenue: by Geography 2020
  • Figure 34. Eli Lilly and Co. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Eli Lilly and Co. (United States) Revenue: by Geography 2020
  • Figure 36. Global Topical Hydrocortisone: by Application USD Million (2021-2026)
  • Figure 37. Global Topical Hydrocortisone: by Form USD Million (2021-2026)
  • Figure 38. Global Topical Hydrocortisone: by End User USD Million (2021-2026)
  • Figure 39. South America Topical Hydrocortisone Share (%), by Country
  • Figure 40. Asia Pacific Topical Hydrocortisone Share (%), by Country
  • Figure 41. Europe Topical Hydrocortisone Share (%), by Country
  • Figure 42. MEA Topical Hydrocortisone Share (%), by Country
  • Figure 43. North America Topical Hydrocortisone Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Pfizer Inc (United States)
  • AstraZeneca plc. (United Kingdom)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Taro Pharmaceutical Industries Ltd. (United States)
  • Merck & Co., Inc.(United States)
  • Actimis Pharmaceuticals (Germany)
  • Siemens Healthcare (Germany)
  • Sanofi (France)
  • Novartis International AG (Switzerland)
  • Eli Lilly and Co. (United States)
Select User Access Type

Key Highlights of Report


Apr 2021 216 Pages 59 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Topical Hydrocortisone Market Quantitative research analysis
Global Topical Hydrocortisone Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Topical Hydrocortisone Market Report?

Have a Query? Click Here

Other Related Reports

Myxedema Coma Comprehensive Study by (), Route of Administration (Oral, Injectable), Indication (Hypothyroidism, Hypocortisolemia, Hyponatremia, Hypoventilation, Hypothermia, Hypoglycemia, Hypotensi...
$ 3650
Ibuprofen Lysine Comprehensive Study by Application (Adults, Children), Route of Administration (Injection, Tablet), Distribution Channel (Online, Hospital Pharmacies, Retail Pharmacies), Strength (6...
$ 3350
Rivaroxaban Comprehensive Study by Application (Deep Vein Thrombosis Prophylaxis, Pulmonary Embolism), Distribution Channel (Online, Hospital Pharmacies), Strength (2.5 mg, 10 mg, 15 mg, 20 mg) Playe...
$ 3500
Revivable Yeast Comprehensive Study by Application (Food and Beverages, Cosmetics and Skincare, Pharmaceuticals, Other), Nature (Organic, Conventional), Form (Powder, Paste, Tablet, Capsule, Other), ...
$ 3450
Ampicillin Drugs Comprehensive Study by Indication (Infection (Intestine, Stomach, Bladder, and Others), Meningitis, Gonorrhea, Pneumonia, Others), Distribution Channel (Hospital Pharmacies, Retail P...
$ 3450
Heartworm Treatment Products Comprehensive Study by Type (Chewable (Fluralaner, Valerian, Chamomile), Spot on (Methoprene, Fipronil, Moxidectin)), Application (Dog, Cats, Others), Distribution Channe...
$ 3450